Published: 22 February 2023
Author(s): Antonio D'Alessio, Antonella Cammarota, Lorenza Rimassa
Issue: May 2023
Section: Commentary

The treatment landscape of advanced hepatocellular carcinoma (HCC) has become increasingly complex over the past few years [1]. After the decade-long multi-kinase inhibitor (MKI) monopoly of sorafenib and lenvatinib, first-line HCC entered its immunotherapy era with the approval by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) of the combination of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody (mAb) atezolizumab and the anti-vascular endothelial growth factor (VEGF) bevacizumab as first-line treatment for unresectable or metastatic HCC [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.